Therapeutic potential of protease-activated receptor-1 antagonists

被引:0
|
作者
Derian, CK [1 ]
Maryanoff, BE [1 ]
Zhang, HC [1 ]
Andrade-Gordon, P [1 ]
机构
[1] Johnson & Johnson Pharmaceut Res & Dev, Drug Discovery, Spring House, PA 19477 USA
关键词
platelets; protease-activated receptor; thrombin; vascular;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The serine protease thrombin (EC 3.4.21.5) is central to the maintenance of haemostatic balance through its coagulant, anticoagulant and platelet activating properties. In addition, this enzyme affects numerous cellular responses in a wide variety of cells, such as cell proliferation, cytokine and growth factor release, lipid metabolism and tissue remodelling. A family of G-protein-coupled protease-activated receptors (PARs) mediates these cellular actions of thrombin. While thrombin can activate three of the four PAR family members, PAR-1 represents the primary thrombin-responsive receptor in human cells. The expression of PAR-1 in platelets, the vasculature and myocardium, in cells within atherosclerotic plaque and tissues after vascular injury, indicates that this receptor plays an important role during the response to tissue injury and associated inflammatory processes. With the development of PAR-deficient mice and small-molecule antagonists, it is now clear that intervening in processes mediated by PAR-1 presents a new approach to treating a variety of disorders dependent on thrombin generation, including thrombosis and restenosis. The full potential of PAR-1 antagonists has yet to be realised, but the promise of novel therapeutics that modulate receptor function rather than thrombin's proteolytic activity, provides an alternative and, perhaps, more desirable means to dampen the pathological effects of thrombin.
引用
收藏
页码:209 / 221
页数:13
相关论文
共 50 条
  • [31] βarrestins regulate protease-activated receptor-1 desensitization but not internalization or downregulation
    Paing, MM
    Stutts, AB
    Kohout, TA
    Robert, LJ
    Trejo, J
    MOLECULAR BIOLOGY OF THE CELL, 2001, 12 : 342A - 342A
  • [32] Protease-activated receptor-1 activation causes venoconstriction in vivo in man
    Gudmundsdottir, I
    Webb, D
    Newby, D
    HEART, 2006, 92 : A111 - A111
  • [33] Staphylokinase activates platelets by cleaving the thrombin protease-activated receptor-1
    McRedmond, JP
    Harriot, P
    Walker, B
    Fitzgerald, DJ
    CIRCULATION, 1997, 96 (08) : 3121 - 3121
  • [34] Role of ubiquitination in the regulation of protease-activated receptor-1 signaling and trafficking
    Wolfe, BL
    Trejo, J
    MOLECULAR BIOLOGY OF THE CELL, 2004, 15 : 436A - 436A
  • [35] Sorting nexin 1 associates with protease-activated receptor-1 and regulates downregulation
    Wang, YJ
    Szabo, K
    Haft, CR
    Trejo, J
    MOLECULAR BIOLOGY OF THE CELL, 2001, 12 : 123A - 123A
  • [36] Function of sorting nexins 1 and 2 in trafficking of protease-activated receptor-1
    Trejo, J
    Gullapalli, A
    MOLECULAR BIOLOGY OF THE CELL, 2004, 15 : 438A - 438A
  • [37] Protease-Activated Receptor 1 (PAR-1) Antagonists as Potential Treatment for Acute Coronary Syndrome
    Abdel-Magid, Ahmed F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (10): : 881 - 883
  • [38] Thrombin-Induced Cerebral Hemorrhage: Role of Protease-Activated Receptor-1
    Cheng, Yingying
    Xi, Guohua
    Jin, Hang
    Keep, Richard F.
    Feng, Jiachun
    Hua, Ya
    TRANSLATIONAL STROKE RESEARCH, 2014, 5 (04) : 472 - 475
  • [39] Thrombin-Induced Cerebral Hemorrhage: Role of Protease-Activated Receptor-1
    Yingying Cheng
    Guohua Xi
    Hang Jin
    Richard F. Keep
    Jiachun Feng
    Ya Hua
    Translational Stroke Research, 2014, 5 : 472 - 475
  • [40] Protease-Activated Receptor-1 Deficiency Reduces Doxorubicin-Induced Cardiotoxicity
    Antoniak, Silvio
    Mackman, Nigel
    CIRCULATION, 2013, 128 (22)